Edgewise Therapeutics Yönetim
Yönetim kriter kontrolleri 4/4
Edgewise Therapeutics CEO'su Kevin Koch, Aug2017 tarihinde atandı, in görev süresi 7.25 yıldır. in toplam yıllık tazminatı $ 3.98M olup, şirket hissesi ve opsiyonları dahil olmak üzere 15% maaş ve 85% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.37% ine doğrudan sahiptir ve bu hisseler $ 11.38M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.2 yıl ve 4.8 yıldır.
Anahtar bilgiler
Kevin Koch
İcra Kurulu Başkanı
US$4.0m
Toplam tazminat
| CEO maaş yüzdesi | 15.0% |
| CEO görev süresi | 7.3yrs |
| CEO sahipliği | 0.4% |
| Yönetim ortalama görev süresi | 4.2yrs |
| Yönetim Kurulu ortalama görev süresi | 4.8yrs |
Son yönetim güncellemeleri
Recent updates
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation
Nov 26
Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)
Sep 19We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Aug 12Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal
Aug 05Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run
May 10We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate
May 10Edgewise Therapeutics: Behind The Massive Rally
Feb 18Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Dec 07Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans
Aug 16Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Apr 28We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Jan 13Edgewise Therapeutics proposes $100M stock offering plan
Sep 13Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02
Aug 04Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Aug 02We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Mar 24We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Nov 23Edgewise Therapeutics names new chief medical officer
Apr 27CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$116m |
| Mar 31 2024 | n/a | n/a | -US$106m |
| Dec 31 2023 | US$4m | US$595k | -US$100m |
| Sep 30 2023 | n/a | n/a | -US$89m |
| Jun 30 2023 | n/a | n/a | -US$81m |
| Mar 31 2023 | n/a | n/a | -US$76m |
| Dec 31 2022 | US$5m | US$572k | -US$68m |
| Sep 30 2022 | n/a | n/a | -US$61m |
| Jun 30 2022 | n/a | n/a | -US$56m |
| Mar 31 2022 | n/a | n/a | -US$51m |
| Dec 31 2021 | US$5m | US$525k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$36m |
| Jun 30 2021 | n/a | n/a | -US$27m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$2m | US$425k | -US$17m |
| Dec 31 2019 | US$741k | US$425k | -US$10m |
Tazminat ve Piyasa: Kevin 'nin toplam tazminatı ($USD 3.98M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 6.54M ).
Tazminat ve Kazançlar: Kevin 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Kevin Koch (64 yo)
7.3yrs
Görev süresi
US$3,975,855
Tazminat
Dr. Kevin Koch, Ph.D. is a Venture Partner at OrbiMed Advisors, LLC. He has been a Member of Scientific Advisory Board at OnKure, Inc. Dr. Koch serves as a Member of Scientific Advisory Board at Frontier M...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 7.5yrs | US$226.00k | 0% $ 0 | |
| President | 7.3yrs | US$3.98m | 0.37% $ 11.4m | |
| Co-Founder & Independent Director | 7.5yrs | US$193.00k | 0.021% $ 638.1k | |
| Chief Business Officer | 4.2yrs | US$1.76m | 0.016% $ 486.9k | |
| Chief Medical Officer | 3.6yrs | US$1.72m | 0.015% $ 468.0k | |
| Co-Founder | 7.4yrs | US$2.46m | 0.013% $ 409.5k | |
| Chief Financial Officer | 4.2yrs | US$772.02k | 0.081% $ 2.5m | |
| General Counsel | 4.2yrs | Veri yok | 0.0034% $ 104.6k | |
| Chief Development Officer | 1.9yrs | Veri yok | Veri yok |
4.2yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş
Deneyimli Yönetim: EWTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 7.5yrs | US$226.00k | 0% $ 0 | |
| President | 7.4yrs | US$3.98m | 0.37% $ 11.4m | |
| Co-Founder & Independent Director | 3.8yrs | US$193.00k | 0.021% $ 638.1k | |
| Co-Founder | 7.3yrs | US$2.46m | 0.013% $ 409.5k | |
| Independent Director | 5.3yrs | US$199.50k | 0.017% $ 503.1k | |
| Independent Director | 3.9yrs | US$208.00k | 0% $ 0 | |
| Director | less than a year | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 1.7yrs | US$485.00k | 0.011% $ 349.7k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | 4.8yrs | Veri yok | Veri yok |
4.8yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: EWTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).